


# INVITATION

## NOVARTIS-SPONSORED VIRTUAL SATELLITE SYMPOSIUM

at the ESH 2021 E-Conference

“How I Manage CAR-T Therapies and Bispecific Antibodies for my Patients”



## CAR-T cells in DLBCL: Timing is key for success!

18.55–19.55 CEST | Monday 6<sup>th</sup> September 2021

[REGISTER FOR FREE NOW](#)

CAR-T, chimeric antigen receptor T-cell; DLBCL, diffuse large B-cell lymphoma; ESH, European School of Haematology.

 **NOVARTIS**

Novartis Pharma AG  
CH-4002 Basel Switzerland

© 2021 Novartis

08/21

143282

# CAR-T cells in DLBCL: Timing is key for success!

at the ESH 2021 E-Conference

“How I Manage CAR-T Therapies and Bispecific Antibodies for my Patients”  
on Monday 6<sup>th</sup> September 2021 at 18.55–19.55 CEST

[REGISTER FOR FREE NOW](#)

The esteemed faculty, **Professor Lenz** and **Professor von Tresckow**, invite you to join this live interactive discussion facilitated by the health and medical journalist **Dr Jarvis, MBE**. Throughout the meeting, our expert panel will:

- Examine the concept of T-cell fitness and its potential impact on CAR-T therapy for the treatment of DLBCL
- Explore the effect of prior therapies received before apheresis and CAR-T infusion on T-cell fitness and consider practical implications to ensure optimal patient management
- Discuss how the referral process may play a key role in the timely identification of patients potentially eligible for CAR-T therapy and ways to improve this

## AGENDA

### WELCOME AND INTRODUCTION

Chair: S. Jarvis (UK)

### HOW FIT IS FIT? T-CELL FITNESS (MATTERS)

B. v Tresckow (Germany)

### DO PRIOR THERAPIES HAVE AN EFFECT ON T CELLS?

G. Lenz (Germany)

### CAN AN EFFICIENT REFERRAL PATH POTENTIALLY IMPROVE THE OUTCOME OF CAR-T THERAPY?

B. v Tresckow

### ROUND-TABLE DISCUSSION

All speakers  
Moderated by S. Jarvis

CAR-T, chimeric antigen receptor T-cell; DLBCL, diffuse large B-cell lymphoma; ESH, European School of Haematology.

